| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enzyme Inhibitors | 11 | 2025 | 457 | 2.110 |
Why?
|
| Antineoplastic Agents | 17 | 2025 | 979 | 2.050 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2025 | 19 | 1.830 |
Why?
|
| Prostatic Neoplasms | 14 | 2022 | 1068 | 1.760 |
Why?
|
| Naphthoquinones | 5 | 2020 | 41 | 1.590 |
Why?
|
| Apoptosis | 11 | 2025 | 1541 | 1.350 |
Why?
|
| Benzamides | 6 | 2018 | 78 | 1.250 |
Why?
|
| Receptors, Calcitriol | 5 | 2024 | 69 | 1.140 |
Why?
|
| Cell Line, Tumor | 30 | 2025 | 2598 | 1.050 |
Why?
|
| Pyridones | 6 | 2018 | 50 | 1.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2025 | 28 | 0.900 |
Why?
|
| Microsatellite Instability | 1 | 2025 | 47 | 0.900 |
Why?
|
| MicroRNAs | 4 | 2024 | 501 | 0.880 |
Why?
|
| Humans | 73 | 2025 | 42163 | 0.840 |
Why?
|
| Parkinson Disease | 3 | 2022 | 207 | 0.830 |
Why?
|
| Breast Neoplasms | 6 | 2025 | 1679 | 0.790 |
Why?
|
| Vitamin D | 3 | 2022 | 196 | 0.780 |
Why?
|
| Exercise | 7 | 2023 | 674 | 0.780 |
Why?
|
| Neoplasms | 3 | 2024 | 1341 | 0.710 |
Why?
|
| Cell Proliferation | 15 | 2025 | 1420 | 0.680 |
Why?
|
| Tamoxifen | 1 | 2020 | 67 | 0.660 |
Why?
|
| Neuroprotective Agents | 4 | 2022 | 267 | 0.630 |
Why?
|
| Nicotine | 5 | 2020 | 290 | 0.630 |
Why?
|
| Antiparkinson Agents | 1 | 2019 | 14 | 0.620 |
Why?
|
| Nerve Growth Factors | 1 | 2019 | 34 | 0.610 |
Why?
|
| Isoquinolines | 3 | 2015 | 50 | 0.610 |
Why?
|
| Colorectal Neoplasms | 1 | 2025 | 502 | 0.600 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 61 | 0.600 |
Why?
|
| Emetine | 2 | 2015 | 13 | 0.590 |
Why?
|
| Methyltransferases | 6 | 2019 | 66 | 0.560 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2025 | 339 | 0.540 |
Why?
|
| Social Support | 1 | 2020 | 438 | 0.530 |
Why?
|
| S-Adenosylhomocysteine | 2 | 2019 | 11 | 0.530 |
Why?
|
| Wasps | 3 | 2024 | 27 | 0.530 |
Why?
|
| Methylation | 12 | 2019 | 118 | 0.520 |
Why?
|
| Histones | 7 | 2017 | 194 | 0.510 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2017 | 458 | 0.510 |
Why?
|
| Depression | 3 | 2022 | 837 | 0.500 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2016 | 122 | 0.500 |
Why?
|
| Mental Disorders | 1 | 2020 | 377 | 0.500 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 454 | 0.500 |
Why?
|
| RNA | 1 | 2018 | 266 | 0.490 |
Why?
|
| Enzyme Assays | 1 | 2016 | 13 | 0.490 |
Why?
|
| Ditiocarb | 1 | 2015 | 4 | 0.480 |
Why?
|
| Lymphoma, B-Cell | 2 | 2018 | 28 | 0.480 |
Why?
|
| Cell Survival | 7 | 2020 | 934 | 0.470 |
Why?
|
| Suntan | 1 | 2014 | 5 | 0.450 |
Why?
|
| Inhibitory Concentration 50 | 6 | 2020 | 98 | 0.450 |
Why?
|
| Histone-Lysine N-Methyltransferase | 6 | 2018 | 30 | 0.450 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2024 | 860 | 0.440 |
Why?
|
| Lysine | 4 | 2017 | 120 | 0.400 |
Why?
|
| Neoplasm Proteins | 2 | 2025 | 228 | 0.400 |
Why?
|
| Animals | 23 | 2025 | 16695 | 0.390 |
Why?
|
| Point Mutation | 3 | 2014 | 98 | 0.380 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2024 | 727 | 0.370 |
Why?
|
| Male | 28 | 2025 | 22779 | 0.370 |
Why?
|
| Pyrimidines | 3 | 2017 | 130 | 0.360 |
Why?
|
| Female | 25 | 2025 | 24018 | 0.350 |
Why?
|
| Schizophrenia | 2 | 2023 | 91 | 0.340 |
Why?
|
| Bipolar Disorder | 2 | 2023 | 83 | 0.340 |
Why?
|
| Neuroblastoma | 4 | 2022 | 134 | 0.340 |
Why?
|
| Benzimidazoles | 3 | 2017 | 41 | 0.340 |
Why?
|
| Biphenyl Compounds | 7 | 2018 | 52 | 0.340 |
Why?
|
| Androgens | 2 | 2011 | 107 | 0.330 |
Why?
|
| DNA Methylation | 4 | 2025 | 393 | 0.330 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2010 | 18 | 0.320 |
Why?
|
| Promoter Regions, Genetic | 3 | 2025 | 534 | 0.320 |
Why?
|
| Quality of Life | 3 | 2025 | 599 | 0.310 |
Why?
|
| Mice | 11 | 2025 | 6490 | 0.310 |
Why?
|
| Crystallography, X-Ray | 5 | 2025 | 285 | 0.310 |
Why?
|
| Structure-Activity Relationship | 6 | 2025 | 491 | 0.310 |
Why?
|
| Neurotoxins | 2 | 2007 | 55 | 0.300 |
Why?
|
| Cell Cycle | 6 | 2014 | 348 | 0.300 |
Why?
|
| Adult | 14 | 2025 | 13458 | 0.290 |
Why?
|
| Protein-Arginine N-Methyltransferases | 2 | 2019 | 7 | 0.270 |
Why?
|
| Ultraviolet Rays | 2 | 2020 | 118 | 0.270 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 557 | 0.260 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 3 | 2017 | 7 | 0.260 |
Why?
|
| Drug Synergism | 4 | 2020 | 189 | 0.260 |
Why?
|
| Mice, Nude | 3 | 2025 | 403 | 0.250 |
Why?
|
| Drug Discovery | 2 | 2025 | 106 | 0.250 |
Why?
|
| Middle Aged | 16 | 2025 | 11819 | 0.250 |
Why?
|
| Kinetics | 4 | 2016 | 698 | 0.250 |
Why?
|
| Ethanol | 3 | 2021 | 221 | 0.250 |
Why?
|
| Exercise Therapy | 2 | 2024 | 83 | 0.250 |
Why?
|
| RNA, Messenger | 5 | 2021 | 1265 | 0.240 |
Why?
|
| Morpholines | 5 | 2018 | 73 | 0.240 |
Why?
|
| Transcription Factors | 1 | 2010 | 722 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 358 | 0.240 |
Why?
|
| Allosteric Regulation | 1 | 2025 | 27 | 0.230 |
Why?
|
| Exoribonucleases | 1 | 2025 | 10 | 0.230 |
Why?
|
| Small Molecule Libraries | 3 | 2018 | 60 | 0.230 |
Why?
|
| Fibroadenoma | 1 | 2025 | 4 | 0.230 |
Why?
|
| Leukemia | 2 | 2017 | 54 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2018 | 1112 | 0.220 |
Why?
|
| Aspartic Acid Endopeptidases | 2 | 2011 | 19 | 0.220 |
Why?
|
| Cadmium | 1 | 2024 | 54 | 0.220 |
Why?
|
| Administration, Oral | 1 | 2025 | 256 | 0.220 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 933 | 0.220 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2014 | 40 | 0.210 |
Why?
|
| Estrogen Receptor alpha | 1 | 2025 | 120 | 0.210 |
Why?
|
| Consensus | 1 | 2024 | 53 | 0.210 |
Why?
|
| Aged | 11 | 2025 | 7982 | 0.210 |
Why?
|
| Receptors, Estrogen | 1 | 2024 | 177 | 0.200 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 130 | 0.200 |
Why?
|
| Parasites | 1 | 2023 | 36 | 0.200 |
Why?
|
| Drosophilidae | 1 | 2022 | 1 | 0.200 |
Why?
|
| Postoperative Complications | 1 | 2024 | 253 | 0.190 |
Why?
|
| Blotting, Western | 3 | 2010 | 884 | 0.190 |
Why?
|
| Sports | 1 | 2023 | 53 | 0.190 |
Why?
|
| Cell Death | 6 | 2020 | 277 | 0.180 |
Why?
|
| Calcium | 1 | 2024 | 487 | 0.180 |
Why?
|
| Prognosis | 3 | 2021 | 850 | 0.180 |
Why?
|
| Butyric Acid | 1 | 2021 | 19 | 0.180 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 522 | 0.180 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 138 | 0.180 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2021 | 37 | 0.180 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 708 | 0.170 |
Why?
|
| Qualitative Research | 2 | 2021 | 526 | 0.170 |
Why?
|
| Sunbathing | 1 | 2020 | 8 | 0.170 |
Why?
|
| Binding Sites | 3 | 2016 | 670 | 0.170 |
Why?
|
| Pulmonary Medicine | 1 | 2020 | 4 | 0.170 |
Why?
|
| Sports Medicine | 1 | 2020 | 6 | 0.170 |
Why?
|
| Quarantine | 1 | 2020 | 8 | 0.170 |
Why?
|
| Receptor, erbB-2 | 1 | 2021 | 149 | 0.170 |
Why?
|
| Butyrates | 1 | 2020 | 34 | 0.160 |
Why?
|
| Risk | 3 | 2015 | 289 | 0.160 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 683 | 0.160 |
Why?
|
| Mass Spectrometry | 2 | 2019 | 279 | 0.160 |
Why?
|
| Gene Rearrangement | 2 | 2017 | 16 | 0.160 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2019 | 2 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2025 | 479 | 0.160 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2019 | 30 | 0.160 |
Why?
|
| Psychotic Disorders | 1 | 2020 | 69 | 0.160 |
Why?
|
| Receptors, Nicotinic | 1 | 2020 | 114 | 0.150 |
Why?
|
| Case-Control Studies | 5 | 2024 | 1266 | 0.150 |
Why?
|
| Depressive Disorder, Major | 1 | 2020 | 128 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 81 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 86 | 0.150 |
Why?
|
| Dopamine | 3 | 2022 | 272 | 0.140 |
Why?
|
| Microfluidics | 1 | 2018 | 45 | 0.140 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2017 | 11 | 0.140 |
Why?
|
| Guanylate Cyclase | 1 | 2017 | 21 | 0.140 |
Why?
|
| Isoxazoles | 1 | 2017 | 14 | 0.140 |
Why?
|
| Spiro Compounds | 1 | 2017 | 15 | 0.140 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2011 | 35 | 0.140 |
Why?
|
| Reactive Oxygen Species | 1 | 2020 | 518 | 0.140 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 21 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 45 | 0.140 |
Why?
|
| Prostate-Specific Antigen | 2 | 2015 | 145 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2017 | 93 | 0.130 |
Why?
|
| Neoplasm Transplantation | 5 | 2017 | 129 | 0.130 |
Why?
|
| Catalysis | 2 | 2010 | 191 | 0.130 |
Why?
|
| Comorbidity | 1 | 2019 | 725 | 0.130 |
Why?
|
| Sarcoma, Synovial | 1 | 2016 | 2 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2009 | 411 | 0.130 |
Why?
|
| Binding, Competitive | 1 | 2016 | 107 | 0.120 |
Why?
|
| Molecular Probes | 1 | 2015 | 23 | 0.120 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2015 | 5 | 0.120 |
Why?
|
| Occupational Health | 1 | 2015 | 30 | 0.120 |
Why?
|
| Zanthoxylum | 1 | 2015 | 4 | 0.120 |
Why?
|
| Prostatic Hyperplasia | 1 | 2015 | 32 | 0.120 |
Why?
|
| Information Dissemination | 1 | 2015 | 66 | 0.110 |
Why?
|
| Sunlight | 1 | 2014 | 48 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 290 | 0.110 |
Why?
|
| Cockroaches | 1 | 2014 | 8 | 0.110 |
Why?
|
| Growth Inhibitors | 1 | 2014 | 29 | 0.110 |
Why?
|
| Protein Binding | 4 | 2019 | 1076 | 0.110 |
Why?
|
| Workplace | 1 | 2015 | 86 | 0.110 |
Why?
|
| Preoperative Care | 2 | 2024 | 31 | 0.110 |
Why?
|
| Metabolomics | 1 | 2014 | 90 | 0.110 |
Why?
|
| Nucleus Accumbens | 2 | 2007 | 99 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2014 | 36 | 0.110 |
Why?
|
| Age Factors | 1 | 2017 | 1139 | 0.110 |
Why?
|
| Rhabdoid Tumor | 1 | 2013 | 2 | 0.100 |
Why?
|
| Smoking | 1 | 2020 | 1019 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2015 | 318 | 0.100 |
Why?
|
| Indazoles | 1 | 2012 | 10 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 209 | 0.100 |
Why?
|
| Lymphoma | 1 | 2012 | 38 | 0.100 |
Why?
|
| Eye Infections, Viral | 1 | 2012 | 4 | 0.090 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 44 | 0.090 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2011 | 1 | 0.090 |
Why?
|
| Plant Extracts | 1 | 2015 | 303 | 0.090 |
Why?
|
| Diamines | 1 | 2011 | 8 | 0.090 |
Why?
|
| Benzoxazoles | 1 | 2011 | 10 | 0.090 |
Why?
|
| Oxazoles | 1 | 2011 | 19 | 0.090 |
Why?
|
| Models, Molecular | 4 | 2019 | 875 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2015 | 467 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2025 | 222 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 111 | 0.080 |
Why?
|
| Molecular Structure | 3 | 2019 | 560 | 0.080 |
Why?
|
| Central Nervous System Depressants | 2 | 2007 | 42 | 0.080 |
Why?
|
| Phylogeny | 2 | 2023 | 740 | 0.080 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2009 | 9 | 0.080 |
Why?
|
| Nicotinic Agonists | 2 | 2007 | 87 | 0.070 |
Why?
|
| Catalytic Domain | 2 | 2014 | 118 | 0.070 |
Why?
|
| Drug Interactions | 2 | 2007 | 151 | 0.070 |
Why?
|
| RNA Interference | 2 | 2021 | 246 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 506 | 0.070 |
Why?
|
| Oxadiazoles | 1 | 2008 | 15 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 456 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 649 | 0.070 |
Why?
|
| Mice, SCID | 3 | 2014 | 158 | 0.070 |
Why?
|
| Drug Design | 3 | 2015 | 183 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 2803 | 0.070 |
Why?
|
| Genotype | 2 | 2024 | 796 | 0.070 |
Why?
|
| Annexin A5 | 1 | 2007 | 27 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 2 | 2012 | 427 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 159 | 0.070 |
Why?
|
| Retinoblastoma Protein | 1 | 2007 | 29 | 0.070 |
Why?
|
| Parkinsonian Disorders | 1 | 2007 | 42 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 79 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2007 | 88 | 0.060 |
Why?
|
| Adenosine Triphosphate | 1 | 2007 | 205 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 297 | 0.060 |
Why?
|
| Time Factors | 2 | 2018 | 1848 | 0.060 |
Why?
|
| Tetrazolium Salts | 1 | 2005 | 36 | 0.060 |
Why?
|
| Conotoxins | 1 | 2005 | 20 | 0.060 |
Why?
|
| Rats | 5 | 2014 | 3701 | 0.060 |
Why?
|
| Thiazoles | 1 | 2005 | 76 | 0.060 |
Why?
|
| Glucagon | 1 | 2024 | 7 | 0.060 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2017 | 8 | 0.060 |
Why?
|
| Hep G2 Cells | 1 | 2024 | 62 | 0.060 |
Why?
|
| Hymenoptera | 1 | 2024 | 6 | 0.050 |
Why?
|
| Substrate Specificity | 2 | 2019 | 217 | 0.050 |
Why?
|
| Animal Structures | 1 | 2024 | 21 | 0.050 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2025 | 95 | 0.050 |
Why?
|
| Kenya | 1 | 2024 | 56 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2016 | 15 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2024 | 40 | 0.050 |
Why?
|
| Body Size | 1 | 2024 | 47 | 0.050 |
Why?
|
| Organ Size | 1 | 2024 | 167 | 0.050 |
Why?
|
| Iran | 1 | 2024 | 199 | 0.050 |
Why?
|
| European Union | 1 | 2023 | 6 | 0.050 |
Why?
|
| Scattering, Radiation | 1 | 2003 | 43 | 0.050 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2024 | 183 | 0.050 |
Why?
|
| CHO Cells | 1 | 2003 | 123 | 0.050 |
Why?
|
| Endopeptidases | 1 | 2003 | 63 | 0.050 |
Why?
|
| Glycosylation | 1 | 2003 | 111 | 0.050 |
Why?
|
| Acetic Acid | 1 | 2022 | 19 | 0.050 |
Why?
|
| Cricetinae | 1 | 2003 | 241 | 0.050 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2022 | 81 | 0.050 |
Why?
|
| Lipid Bilayers | 1 | 2003 | 56 | 0.050 |
Why?
|
| Disease Progression | 1 | 2025 | 661 | 0.050 |
Why?
|
| Light | 1 | 2003 | 182 | 0.050 |
Why?
|
| Drosophila | 1 | 2003 | 150 | 0.050 |
Why?
|
| Ventral Tegmental Area | 1 | 2002 | 47 | 0.050 |
Why?
|
| Ligands | 1 | 2003 | 387 | 0.040 |
Why?
|
| Rehabilitation | 1 | 2021 | 5 | 0.040 |
Why?
|
| Genomics | 1 | 2023 | 289 | 0.040 |
Why?
|
| ROC Curve | 1 | 2021 | 157 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 3942 | 0.040 |
Why?
|
| Organizational Policy | 1 | 2021 | 26 | 0.040 |
Why?
|
| Exercise Tolerance | 1 | 2021 | 22 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2017 | 1737 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2021 | 30 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2003 | 400 | 0.040 |
Why?
|
| State Medicine | 1 | 2020 | 9 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 2020 | 22 | 0.040 |
Why?
|
| Alzheimer Disease | 2 | 2011 | 972 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2025 | 1574 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2022 | 928 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 3077 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2003 | 461 | 0.040 |
Why?
|
| Peptides | 1 | 2003 | 357 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2020 | 2111 | 0.040 |
Why?
|
| RNA Stability | 1 | 2019 | 28 | 0.040 |
Why?
|
| Adenosine | 1 | 2019 | 62 | 0.040 |
Why?
|
| Multiprotein Complexes | 1 | 2019 | 55 | 0.040 |
Why?
|
| Health Policy | 1 | 2021 | 184 | 0.040 |
Why?
|
| Cell Line | 1 | 2003 | 1416 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2019 | 157 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2019 | 92 | 0.040 |
Why?
|
| Computational Biology | 1 | 2021 | 324 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2018 | 9 | 0.040 |
Why?
|
| Mental Health | 1 | 2023 | 363 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 203 | 0.040 |
Why?
|
| Osteonectin | 1 | 2018 | 10 | 0.040 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2018 | 27 | 0.040 |
Why?
|
| Cell Size | 1 | 2018 | 46 | 0.040 |
Why?
|
| France | 1 | 2018 | 21 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 11 | 0.040 |
Why?
|
| Mutation | 2 | 2017 | 1169 | 0.040 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2018 | 37 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2018 | 146 | 0.040 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2018 | 83 | 0.030 |
Why?
|
| Cadherins | 1 | 2018 | 102 | 0.030 |
Why?
|
| HIV Infections | 1 | 2012 | 2535 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 303 | 0.030 |
Why?
|
| Adenine | 1 | 2017 | 48 | 0.030 |
Why?
|
| Lung | 1 | 2020 | 484 | 0.030 |
Why?
|
| Telemedicine | 1 | 2021 | 215 | 0.030 |
Why?
|
| Adolescent | 2 | 2023 | 5950 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 116 | 0.030 |
Why?
|
| Piperidines | 1 | 2017 | 80 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 183 | 0.030 |
Why?
|
| Intellectual Property | 1 | 2015 | 2 | 0.030 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2015 | 4 | 0.030 |
Why?
|
| Interior Design and Furnishings | 1 | 2015 | 4 | 0.030 |
Why?
|
| snRNP Core Proteins | 1 | 2015 | 12 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2015 | 168 | 0.030 |
Why?
|
| Mecamylamine | 2 | 2007 | 21 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2015 | 61 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2015 | 116 | 0.030 |
Why?
|
| Posture | 1 | 2015 | 61 | 0.030 |
Why?
|
| Vincristine | 1 | 2014 | 14 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 1066 | 0.030 |
Why?
|
| Prednisolone | 1 | 2014 | 16 | 0.030 |
Why?
|
| Nicotinic Antagonists | 2 | 2007 | 36 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 31 | 0.030 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2014 | 34 | 0.030 |
Why?
|
| Dipeptides | 1 | 2014 | 31 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 58 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2014 | 55 | 0.030 |
Why?
|
| NAD | 1 | 2014 | 45 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 686 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 661 | 0.030 |
Why?
|
| Metabolome | 1 | 2014 | 50 | 0.030 |
Why?
|
| Random Allocation | 1 | 2014 | 145 | 0.030 |
Why?
|
| Phytotherapy | 1 | 2015 | 78 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2014 | 92 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 197 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 71 | 0.030 |
Why?
|
| Rats, Wistar | 2 | 2007 | 282 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2014 | 95 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 225 | 0.030 |
Why?
|
| Amino Acids | 1 | 2014 | 150 | 0.030 |
Why?
|
| Glutathione | 1 | 2014 | 170 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 602 | 0.030 |
Why?
|
| Rats, Nude | 1 | 2013 | 6 | 0.030 |
Why?
|
| Internet | 1 | 2015 | 234 | 0.030 |
Why?
|
| Models, Biological | 1 | 2017 | 711 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2018 | 1586 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 284 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2014 | 181 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 448 | 0.030 |
Why?
|
| Plant Roots | 1 | 2015 | 180 | 0.020 |
Why?
|
| Nucleosides | 1 | 2012 | 30 | 0.020 |
Why?
|
| Pyridines | 1 | 2013 | 134 | 0.020 |
Why?
|
| District of Columbia | 1 | 2012 | 73 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2013 | 420 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2015 | 845 | 0.020 |
Why?
|
| Ophthalmology | 1 | 2012 | 34 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 200 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2012 | 117 | 0.020 |
Why?
|
| Phenotype | 1 | 2014 | 774 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1559 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 229 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 274 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 276 | 0.020 |
Why?
|
| Health Promotion | 1 | 2015 | 691 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 1010 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2011 | 633 | 0.020 |
Why?
|
| Microdialysis | 1 | 2007 | 18 | 0.020 |
Why?
|
| Extracellular Space | 1 | 2007 | 36 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2008 | 300 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 1597 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2007 | 147 | 0.020 |
Why?
|
| United States | 1 | 2017 | 5072 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2002 | 102 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 4936 | 0.010 |
Why?
|